Core Viewpoint - The Trump administration is drafting an executive order that will impose three major restrictions on commercial transactions involving Chinese innovative drug patents or rights, focusing on national security reviews by the Committee on Foreign Investment in the United States (CFIUS) [1][2]. Summary by Sections Executive Order Details - The draft includes three main provisions: 1. Inclusion of Chinese innovative drug BD transactions in the CFIUS mandatory review list, ending the previous "low-risk automatic exemption" practice [2]. 2. FDA will implement "racial sensitivity supplementary reviews" for drugs relying on Chinese clinical data, requiring at least 20% comparative data from non-Asian populations [2]. 3. Establishment of a "key drug domestic production fund" to provide production subsidies for 15 categories of drugs, including antibiotics and acetaminophen, while implementing a "domestic priority" principle in federal procurement [2]. Market Reaction - The market reacted swiftly to the policy risks, with the Hong Kong innovative drug index (HK1105) dropping 3.82% on September 11, 2025, and the A-share innovative drug sector (BK1106) declining 2.17%, with over 80% of stocks in the sector experiencing pullbacks [3]. - The following day, the indices showed signs of recovery, indicating investors' responses to policy uncertainties and rational corrections [3]. Globalization Trends - Despite the geopolitical risks, the trend of Chinese innovative drugs going global remains intact, with total license-out transactions to Europe and the U.S. reaching $9.43 billion as of September 2025 [3]. - Major transactions include a $950 million licensing deal between BeiGene and Royalty Pharma, and a $6 billion global licensing agreement between 3SBio and Pfizer, highlighting a shift towards milestone payments and regional licensing [3]. Industry Challenges - The domestic market faces challenges, with annual growth in medical insurance fund spending (approximately 12%) lagging behind the growth in innovative drug R&D investment (approximately 25%) [4]. - The average reduction in medical negotiations remains high at 54%, and commercial health insurance coverage for innovative drugs is below 15%, creating a supply-demand imbalance that necessitates going global [4]. Risk Resilience Assessment - Goldman Sachs has categorized Chinese innovative drug companies into three risk resilience tiers based on their sensitivity to policy changes and operational capabilities [4][5]. - Companies with mature global layouts exhibit the strongest resilience, while those heavily reliant on domestic markets show the weakest resilience [5][10]. Strategic Defense Framework - A three-dimensional defense system is proposed to address risks associated with the executive order, focusing on transaction review, data compliance, and supply chain security [13]. - Strategies include conducting national security risk pre-assessments for transactions over $50 million and establishing partnerships with U.S. law firms to navigate regulatory challenges [14][15]. Conclusion - The construction of a quantifiable "risk resilience index" is essential for Chinese innovative drugs in the global 2.0 era, emphasizing the need for companies to embed policy hedging clauses in transaction structures and consider racial diversity data in clinical stages [23].

Core Insights - As of the end of Q2 2025, the number of active equity fund managers with assets under management exceeding 10 billion yuan reached 84, an increase of 15 from the end of 2024 [1][3] - This new group of fund managers includes both seasoned professionals with extensive research backgrounds and emerging talents who have rapidly grown during recent strong thematic market trends [3][4] Group Characteristics - Notable companies with multiple fund managers on the list include Huatai-PineBridge, China Universal, and Yongying, indicating strong performance in the industry [3] - Common investment targets among these fund managers include stocks like CATL, Shenghong Technology, and Tencent Holdings, reflecting a focus on high-potential sectors [3] Performance Metrics - The structural rally in the A-share market this year has provided significant performance opportunities for active equity investments [3] - The threshold for the top ten performing fund managers who achieved over 10 billion yuan in assets this year was a return of 35.05%, with Zhang Wei from Huatai-PineBridge leading at 75.67% [3][4] Growth in Assets - The top ten new billion-yuan fund managers saw a net growth in assets of at least 3.102 billion yuan, with Zhang Lu and Gao Nan from Yongying leading with increases of 13.388 billion yuan and 10.779 billion yuan, respectively [4] - Zhang Lu's assets grew from 2.025 billion yuan at the beginning of the year to 15.413 billion yuan by the end of Q2, marking a more than sevenfold increase [4] Investment Strategies - Gao Nan's management strategy focuses on a diversified approach, emphasizing growth and consumption sectors, with significant investments in companies benefiting from consumer recovery and AI trends [4] - The emergence of new billion-yuan fund managers reflects a shift towards diverse strategies, where short-term performance can attract large-scale investments, provided there is a clear investment framework [4] Experience and Background - All new billion-yuan fund managers possess at least four years of investment experience, with four having over ten years in the industry, indicating a trend towards experienced professionals in this segment [4]

Core Insights - The report highlights a divergence between domestic and foreign investments in the pharmaceutical sector, suggesting a strategic focus on innovative drug production during market fluctuations [1] - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the broader market, with hospitals, medical devices, and prescription drugs showing relatively better performance [1] - Domestic investors have maintained stable holdings through the Hong Kong Stock Connect, while foreign investments in Hong Kong pharmaceuticals have slightly decreased since mid-year [1] Investment Insights - The report suggests that recent claims by President Trump regarding increased restrictions on importing Chinese pharmaceuticals will have limited actual impact [2] - It recommends gradually positioning in the innovative drug sector during market corrections, focusing on companies like 3SBio and Eucure Biopharma, which have rich short-term catalysts and valuations that do not yet reflect the core value of their major products [2] - The report also identifies CXO companies benefiting from high downstream demand and improved financing conditions, with WuXi AppTec highlighted as a leading player in this segment [2]

（央视财经《经济信息联播》）在生物医药领域，部分国产创新药在疗效上展现出了能媲美 国际药企 明星药品的表现。近年来，有越来越多的国际制药企业斥巨资和中国药企展开合作。 今年年初，中国的人工智能模型DeepSeek以极低的开发成本和强大的性能获得了世界的瞩目，而其实 在生物技术领域，中国也正在迎来类似的"DeepSeek时刻"，中国药企正在从过去的仿制药时代进入到创 新药时代，并且吸引了众多的国际合作。合作的主要形式是授权合作：外方获得在中国以外市场对中方 药品或相关技术，开发、生产及商业化权利。 宏观上来看，美国生物医药数据公司DealForma在今年5月份发布的报告显示：中国生物医药企业在全球 大型授权交易，也就是首付款达到5000万美元或以上的交易中，按数量看占比已达42%，这一比例与去 年的27%和前年的20%相比显著增加。 一些亮眼案例，就例如今年5月辉瑞支付了12.5亿美元的首付款，获得了三生制药一款创新药在海外市 场的授权。此外，今年上半年，美国制药公司艾伯维、默沙东和再生元等和中国药企总计签署了价值数 十亿美元的授权合作协议。 值得一提的是药企阿斯利康，在过去两年间已和十多家中国创新药企达成了授 ...

Core Insights - China's innovative drug sector is experiencing explosive growth, with overseas licensing transaction amounts significantly increasing [1] - In the first half of this year, the transaction amount for innovative drug licensing has already exceeded $66 billion, surpassing the total for the entire previous year [1] - The emergence of AI model DeepSeek has drawn global attention, paralleling the advancements in China's biotechnology sector, marking a transition from generic drugs to innovative drugs [1] Industry Developments - Chinese pharmaceutical companies are attracting numerous international collaborations, indicating a shift in the global perception of China's drug innovation capabilities [1] - Notable partnerships include Pfizer's payment of $1.25 billion for the overseas licensing of an innovative drug from 3SBio in May [1] - Major US pharmaceutical companies such as AbbVie, Merck, and Regeneron have signed licensing agreements worth billions with Chinese firms in the first half of this year [1]

Group 1: Nutritional Functional Food Industry - The nutritional functional food industry in China is experiencing rapid growth, with a market size projected to reach 522.3 billion yuan in 2024 and 720.3 billion yuan by 2029, representing a CAGR of 6.6% from 2024 to 2029 [2][7] - The market for nutritional functional foods specifically is expected to grow from 233.1 billion yuan in 2024 to 349.9 billion yuan in 2029, with a CAGR of 8.5% [7][8] - The industry has established a complete supply chain, including upstream raw material suppliers, midstream manufacturers, and downstream distributors [8][9] - Key companies in the North Exchange related to this industry include Kangbiter, Wuxi Jinghai, and Hengmei Health, each occupying different positions in the supply chain [9] Group 2: PEEK Material Industry - The PEEK material market in China is projected to reach 1.455 billion yuan in 2024, with a year-on-year growth of 21.14% [11] - PEEK materials are widely used in critical components across automotive, electronics, and aerospace sectors, with automotive manufacturing accounting for 27% of global PEEK consumption [11] - The competitive landscape for global PEEK production is characterized by a few strong players, with the UK-based Victrex being the largest producer [11] Group 3: Electronic Industry - Kangguan Technology - Kangguan Technology reported a revenue of 6.935 billion yuan in the first half of 2025, a year-on-year increase of 5.06%, with a net profit of 384 million yuan, down 6.03% [16][17] - The company plans to distribute a cash dividend of 3.60 yuan per 10 shares, reflecting a dividend payout ratio exceeding 65% [16] - The growth in innovative display products is notable, with a revenue increase of 39.16% in the first half of 2025 [17] Group 4: Pharmaceutical Industry - Sanofi Pharmaceutical - Sanofi Pharmaceutical achieved a revenue of 4.355 billion yuan in the first half of 2025, a slight decline of 1.07%, while the net profit increased by 19.13% to 1.358 billion yuan [20][21] - The company’s overseas revenue grew by 70%, with a presence in over 35 countries [21][22] - The company has a rich pipeline of clinical trials, with significant potential for future growth [22][23] Group 5: New Consumption - Chaohongji - Chaohongji has submitted an application for H-share listing, which is expected to enhance its global strategy and brand image [24][25] - The company has expanded its international presence by opening stores in Malaysia, Thailand, and Cambodia, with two stores in Cambodia as of the first half of 2025 [24][25] - The brand is focusing on younger consumers, with a significant portion of its customer base being from the post-80s to post-00s generation [26]

Global Market Overview - The Hang Seng Index closed at 26,439, up 0.19% for the day and up 31.80% year-to-date [2] - The Southbound capital recorded a net inflow of HKD 3.189 billion [2] - The Chinese stock market showed mixed results, with sectors like consumer discretionary and industrial technology rising, while materials, healthcare, and real estate fell [2] Economic Indicators - China's Ministry of Commerce plans to promote orderly opening in the internet and cultural sectors [2] - Japan's government is expected to increase fiscal expansion, with potential tax cuts for households and inflation subsidies [2] - The U.S. retail sales increased by 0.6% month-on-month in August, marking the third consecutive month of exceeding expectations [3] Sector Performance - The automotive sector shows strong potential with companies like Geely Automobile and XPeng Motors rated as "Buy" with target prices indicating significant upside [4] - The equipment manufacturing sector, including companies like SANY International and Zoomlion, is also rated as "Buy" with positive growth forecasts [4] - The consumer discretionary sector, particularly Luckin Coffee and Green Tea Group, is highlighted for its growth potential, with target prices suggesting substantial upside [4] Investment Recommendations - Geely Automobile (175 HK) is rated "Buy" with a target price of HKD 25.00, indicating a 31% upside [4] - SANY International (631 HK) is rated "Buy" with a target price of HKD 8.90, suggesting a 29% upside [4] - Luckin Coffee (LKNCY US) is rated "Buy" with a target price of USD 44.95, indicating a 14% upside [4]

9月17日早盘，港股通创新药板块继续调整。港股通创新药ETF（520880）100%布局创新药研发类公 司，盘中下探2%，现跌逾1%，实时成交超1.8亿元。 值得关注的是，港股通创新药ETF（520880）场内延续宽幅溢价，显示买盘强劲，低吸资金或不在少 数。截至昨日，520880已连续11日吸金，金额合计超6亿元。 成份股方面，大权重龙头股多数下跌，中国生物制药一度下挫逾5%，石药集团、信达生物、康方制 药、三生制药等多股跌逾3%，百济神州逆市翻红。 业绩验证行业高景气，据西南证券统计，港股创新药已进入盈利期。今年上半年，港股创新药板块实现 归母净利润18亿元，利润首次扭亏为盈。当前，创新药产业已步入一个以盈利驱动为主的新周期，基本 面已明确出现拐点。头部企业在商业化产品的推广中实现盈利，海外的授权及全球临床突破也在加速研 发价值的转化。此次产业趋势的变化标志着十年的技术积累正在逐步转化为实际的商业成果。 【国产创新药硬核崛起，配置认准港股通创新药ETF（520880）】 日前，港股通创新药ETF（520880）跟踪的恒生港股通创新药精选指数"提纯"修订生效，完全剔除 CXO，并精选纳入14家创新药研发类公 ...

Group 1: Stock Recommendations - Recommended stocks include Geely Automobile (175 HK), Li Auto (9863 HK), Zoomlion (1157 HK), Sany International (631 HK), and Luckin Coffee (LKNCY US) with "Buy" ratings[5] - Target price for Geely Automobile is set at 25.00, indicating a potential upside of 36%[5] - Luckin Coffee has a target price of 44.95, representing a potential upside of 16%[5] Group 2: Financial Metrics - Geely Automobile has a market capitalization of $24.0 billion and a P/E ratio of 10.50 for FY24A[5] - Li Auto's market cap is $11.0 billion with a projected P/E ratio of 9.90 for FY25E[5] - The average dividend yield for the recommended stocks ranges from 0.0% (Luckin Coffee) to 5.2% (Green Tea Group)[5] Group 3: Performance Overview - The basket of 25 stocks listed in the previous report achieved an average return of 2.5%, compared to the MSCI China Index return of 6.8%[10] - Out of the 25 stocks, 10 outperformed the benchmark index[10] Group 4: Recent Changes - New addition to the recommended stocks is Guoquan Food (2517 HK) with a "Buy" rating[7] - Jiangnan Buyi (3306 HK) has been removed from the recommended list[7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing stable growth in its core business, with significant potential for overseas expansion [5] - The company reported a revenue of 4.355 billion RMB in the first half of 2025, a slight decrease of 1.07% year-on-year, while the net profit attributable to shareholders increased by 24.6% to 1.36 billion RMB [7] - The company has a robust pipeline of clinical trials and innovative products, with a focus on four major areas: hematology and oncology, autoimmune diseases, nephrology, and others [7] Financial Performance Summary - Revenue projections for 2025 are estimated at 19.52 billion RMB, with a year-on-year growth rate of 114.3% [6] - The net profit attributable to shareholders is projected to be 10.46 billion RMB in 2025, reflecting a significant increase of 400.5% [6] - The earnings per share (EPS) is expected to reach 4.30 RMB in 2025, with a projected price-to-earnings (P/E) ratio of 6.92 [6] Key Developments - The company has entered into a licensing agreement with Pfizer for SSGJ-707, a PD-1/VEGF bispecific antibody, which includes an upfront payment of 1.4 billion USD and potential total transaction value exceeding 6 billion USD [7] - The company’s international market presence has expanded to over 35 countries, with overseas revenue growth of 70% [7] - The company’s R&D expenses increased by 15.13% year-on-year, indicating a commitment to innovation [7]